Locus licenses CRISPR tech to Janssen in potential $818m deal

Timo Minssen

Description

Interview on 800 + USD Life Science deal in the CRISPR Antibiotics area

Subject

Antobiotic resistance, Phage therapy, CRISPR Cas 3. IP, Licensing

Period	9 Jan 2019

Keywords

CRISPR Cas 3
IPR
Antibiotic resistance
Phage therapy

Related content

Research output
The revival of Phage Therapy to fight Antimicrobial Resistance – Part I: What are the legal implications?
Research output: Other contribution › Net publication - Internet publication › Research
Clearing a way through the CRISPR patent jungle
Research output: Contribution to journal › Journal article › Research